Boehringer To Profit From Jardiance Well Into Second Half Of Decade
As Drug’s 2022 Sales Exceed €5bn
The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.
